Transgene focuses on the research and development of myvac, its platform of individualized therapeutic vaccines against cancer. The company is currently raising fresh capital to accelerate this program, planning to dedicate 70 % of the new proceeds to myvac’s clinical and technological advancement. Management states that the new cash will extend Transgene’s financial visibility through the beginning of 2028. Beyond myvac, Transgene continues to advance other oncology immunotherapies, though the article centers on the vaccine platform. The firm’s financing strategy includes both new cash and a debt-for-equity swap with a long-time shareholder, strengthening its balance sheet. No operating metrics such as revenue or patient numbers were disclosed in the press coverage.

Total raised

$121M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025